Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection
Open Access
- 21 July 2021
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (8), 684
- https://doi.org/10.3390/jpm11080684
Abstract
Backgrounds and Aim: Metabolic-associated fatty liver dis-ease (MAFLD) is a novel term proposed in 2020 to avoid the exclusion of certain subpopulations, though the application of this term in the real world is very limited. Here, we aimed to evaluate the impact of MAFLD on hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative resection. Methods: Patients with chronic hepatitis B (CHB)-related HCC who received hepatectomy between January 2010 and December 2019 were consecutively selected. The association between histologically proven concurrent MAFLD and clinical outcomes were retrospectively analyzed. Results: Among the 812 eligible patients with CHB-related HCC, 369 (45.4%) were diagnosed with concurrent MAFLD. After a mean follow-up of 65 months, 303 patients (37.3%) developed HCC recurrence, 111 (13.7%) died, and 12 (1.5%) received liver transplantation. Although no differences in the incidences of HCC recurrence (HR: 0.902, 95% CI: 0.719–1.131, p = 0.370) and death or liver transplantation (HR: 0.743, 95% CI: 0.518–1.006, p = 0.107) were observed between patients with and without MAFLD in multivariate analysis, the patients with MAFLD tended to achieve better recurrent-free survival compared to patients without MAFLD. Notably, lean MAFLD (BMI < 23 kg/m2) was a relative risk factor for tumor recurrence (HR: 2.030, 95% CI: 1.117–3.690, p = 0.020) among patients with MAFLD. Conclusions: The overall prognosis in HBV-related early-stage HCC, in terms of HCC recurrence and death or liver transplantation, was not significantly different between patients with and without MAFLD. Among patients with MALFD, lean-MAFLD was a risk factor for HCC recurrence. Further studies are warranted to validate these results.Funding Information
- Ministry of Health and Welfare (MOHW107-TDU-B-212-114022, MOHW108-TDU-B-212-124022, MOHW109-TDU-B-212-134022)
This publication has 36 references indexed in Scilit:
- Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinomaSurgical Oncology, 2015
- Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013The Lancet, 2015
- Recurrence of Hepatocellular Cancer After ResectionAnnals of Surgery, 2015
- 2. Classification and Diagnosis of DiabetesDiabetes Care, 2014
- 379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2014
- Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic ReviewClinical Gastroenterology and Hepatology, 2012
- Hepatocellular carcinomaThe Lancet, 2012
- Management of hepatocellular carcinoma: An updateHepatology, 2011
- Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C‐related small hepatocellular carcinoma in hepatitis B virus endemic areaLiver International, 2005
- Liver Resection for Hepatocellular Carcinoma on CirrhosisAnnals of Surgery, 2003